Home > Signal Pathway > AMQUAR单克隆抗体抑制剂 > AMQUAR 单克隆抗体抑制剂

AMQUAR 单克隆抗体抑制剂

  • Tocilizumab MA1040

    Tocilizumab is an anti-interleukin-6 receptor (IL-6R) monoclonal antibody, currently approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) and rheumatoid arthritis.

  • TrastuzuMab MA1041

    Trastuzumab, an anti- ERBB2 (HER2 or HER-2/neu) humanized monoclonal antibody, is used to treat “HER2-positive” tumors.

  • pembrolizumab MA1042

    Pembrolizumab (MK-3475, lambrolizumab), a highly selective humanized monoclonal immunoglobulin G4 (IgG4)/kappa isotype antibody that blocks the interaction between PD-1 and its ligands, has demonstrated antitumor activity in multiple tumor types.

  • nivolumab(Opdivo) MA1031

    Nivolumab (BMS-936558, MDX-1106, ONO-4538), an anti-PD-1 monoclonal antibody, has been reported to have anti- tumor effects and approved for the treatment of unresectable or metastatic melanoma in treatment-refractory patients.

  • Obinutuzumab MA1032

    Obinutuzumab (Gazyva) is a unique, third-generation, fully humanized glycoengineered IgG1 type II anti-CD20 monoclonal antibody monoclonal antibody, approved in chronic lymphocytic leukemia (B-CLL) and follicular lymphoma (FL).

  • Current page1, Total Pages8, Total Record38 First Prev 12345 Next Last Goto